Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLLПодробнее

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLLПодробнее

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patientsПодробнее

Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLLПодробнее

Relapsed Chronic Lymphocytic LeukemiaПодробнее

Current thought on treating chronic lymphocytic leukemiaПодробнее

Review of NCCN Guidelines for Chronic Lymphocytic Leukemia (CLL) by Dr. Brian KoffmanПодробнее

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patientsПодробнее

Dr. Jones on Studying Venetoclax in R/R CLLПодробнее

Novel options for patients with CLL who relapse after treatment with BTK inhibitors and venetoclaxПодробнее

Jeffrey Jones Discusses Nurses' Impact on Patient ComplianceПодробнее

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLLПодробнее

MCL and CLL: NCCN Guidelines and Treatment OptionsПодробнее

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016Подробнее

Dr Jeffrey Jones (Abstract S429)Подробнее

Dr. Jeffrey Jones on Idelalisib Combinations in CLLПодробнее

OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLLПодробнее

Dr Jones Discusses ibrutinib/bendamustine/rituximab combination for CLLПодробнее

Zanubrutinib for BTK Inhibitor Intolerant Patients with CLL - Dr. Jeff Sharman ASH 2021Подробнее